

Date: September 24, 2026

To
National Stock Exchange of India Ltd
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: MOLBIO

Subject: Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir/Madam,

This is to inform you that, Company is in receipt of disclosure from M/s India Business Excellence Fund III, a scheme of Business Excellence Trust III under Regulation 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended from time to time.

The above-mentioned disclosures are enclosed herewith and we request you to kindly take the same on record.

Thanking You.
Yours Faithfully,

For Molbio Diagnostics Limited

DARSHAN
RAGHUNATH
KAREKAR

Digitally signed by DARSHAN
RAGHUNATH KAREKAR
Date: 2026.09.24 18:07:46
+05'30'

Darshan Raghunath Karekar
Company Secretary & Compliance Officer
M.No: F13569
Place: Verna-Goa

Enclosure:

Disclosure received under Reg 29(2) of the SEBI(Substantial Acquisition of Shares and Takeovers) Regulations, 2011 dated September 24, 2026.

Date: September 24, 2026

To,
Department of Corporate Services
BSE Limited
Phiroz Jeejeebhoy Towers
Dalal Street, Fort, Mumbai - 400001
Scrip Code: 544866
corp.relations@bseindia.com

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai 400051
Symbol: MOLBIO
takeover@nse.co.in

To,
Company Secretary
Molbio Diagnostics Limited
L-46, Phase II D, Verna Industrial Estate,
Verna, Goa - 403722, India
darshan.karekar@molbiodiagnostics.com

Respected Sir/ Madam,

Name of the Company: Molbio Diagnostics Limited

Sub: Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SEBI Takeover Regulations")


We, India Business Excellence Fund III, a scheme of Business Excellence Trust III, one of the shareholders of Molbio Diagnostics Limited (the "Company") hereby file the disclosure in the format prescribed under Regulation 29(2) of the SEBI Takeover Regulations, with respect to sale of equity shares of the Company.

India Business Excellence Fund III, a scheme of Business Excellence Trust III, has disposed of an aggregate 30,00,000 (Thirty Lakhs) equity shares of Company on September 23, 2026 breaching the 2% threshold specified in Regulation 29(2) of the SEBI Takeover Regulations.

We request you to please take this disclosure on record.

Yours Sincerely,

For and on behalf of
India Business Excellence Fund III, a scheme of Business Excellence Trust III
By its Investment Manager M/s. **MO Alternate Investment Advisors Private Limited**


Chief Operating Officer
Name: Bharat Kedia
Place: Mumbai
Date: September 24, 2026

Disclosures under Regulation 29(2) of
SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Molbio Diagnostics Limited		
Name(s) of the acquirer seller and Persons Acting in Concert (PAC) with the acquirer	India Business Excellence Fund III, a scheme of Business Excellence Trust III		
Whether the acquirer Seller belongs to Promoter / Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. NSE Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition / disposal under consideration, holding of:			
a) Shares carrying voting rights	11,52,39,996	11.52%	11.52%
b) Shares in the nature of encumbrance (pledge/ lien/ non- disposal undertaking/ others)	NIL	NIL	N.A
c) Voting rights (VR) otherwise than by shares	NIL	NIL	N.A
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	NIL	NIL	N.A
e) Total (a+b+c+d)	11,52,39,996	11.52%	11.52%
Details of acquisition / sale			
a) Shares carrying voting rights acquired / sold	30,00,000	2.60%	2.60%
b) VRs acquired /sold otherwise than by shares	NIL	NIL	N.A
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	NIL	NIL	N.A
d) Shares encumbered / invoked / released by the acquirer	NIL	NIL	N.A
e) Total (a+b+c+/-d)	30,00,000	2.60%	2.60%

B

After the acquisition / sale, holding of:			
a) Shares carrying voting rights acquired/sold	11,22,39,996	8.92%	8.92%
b) Shares encumbered with the acquirer	NIL	NIL	N.A
c) VRs otherwise than by shares	NIL	NIL	N.A
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	N.A
e) Total (a+b+c+d)	11,22,39,996	8.92%	8.92%
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	September 23, 2026#		
Equity share capital / total voting capital of the TC before the said acquisition / sale	11,52,39,996 equity shares of Face Value of Rs. 10 each amounting to Rs. 115,23,99,960 (Rupees One Hundred and Fifteen Crore Twenty Three Lakhs Ninety Nine Thousand Nine Hundred and Sixty)		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	11,22,39,996 equity shares of Face value of Rs. 10 each amounting to Rs. 112,23,99,960 (Rupees One Hundred and Twelve Crore Twenty Three Lakhs Ninety Nine Thousand Nine Hundred and Sixty)		
Total diluted share/voting capital of the TC after the said acquisition	8.92%		

The Seller has sold as aggregate 30,00,000 (Thirty Lakh) of equity shares of TC and disposals undertaken on September 23, 2026. The disclosure obligation under Regulation 29(2) of the SEBI Takeover Regulations was triggered pursuant to the disposal of 30,00,000 (Thirty Lakh) equity shares of the TC on September 23, 2026, which breaches the 2% threshold.

(*) Total share capital/ voting capital to be taken as per the latest filing done by the Company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For and on behalf of
India Business Excellence Fund III, a scheme of Business Excellence Trust III
By its Investment Manager M/s. MO Alternate Investment Advisors Private Limited


Chief Operating Officer
Name: Bharat Kedia
Place: Mumbai
Date: September 24, 2026